Zhitong Finance App News, Fengyuan Pharmaceutical (000153.SZ) announced that the company received the “Drug Registration Certificate” for the low calcium peritoneal dialysis solution (lactate-G 2.5%) and the “Drug Registration Certificate” for the low calcium peritoneal dialysis solution (lactate-G 1.5%) approved and issued by the State Drug Administration.

According to the announcement, the company's low-calcium peritoneal dialysis solution (lactate-G 1.5%) and low-calcium peritoneal dialysis solution (lactate-G 2.5%), which have obtained a drug registration certificate, are suitable for patients with acute and chronic renal failure requiring continuous unsleeved peritoneal dialysis treatment due to ineffectiveness of non-dialysis treatment.